Abstract

Objectives: In this article, patients with Parkinson’s disease who were using cabergoline and who were followed up in movement disorders department of our clinic were evaluated with respect to the frequency of lower limb oedema and erytromelalgia.

Patients and Methods: Fifty-one patients (27 females, 24 males; mean age 69.6±11.1 years; range 45 to 82 years) with Parkinson’s disease who were using cabergoline were enrolled in the study. The mean duration of cabergoline therapy was 13.2±7.9 months. Two (14.3%) out of 51 patients used cabergoline as monotherapy, 12 (85.7%) used cabergoline in addition to L-dopa in combined therapy. The patients who were using cabergoline were evaluated retrospectively for peripheral oedema and erytromelalgia located on the foot and ankle.

Results: We observed peripheral oedema and/or erytromelalgia in 14 (27.4%) patients. Nine of these patients (17.6%) had only peripheral oedema, and five (9.8%) had erytromelalgia in addition to peripheral oedema.

Conclusion: We conclude that cabergoline use may cause significant peripheral oedema and/or erytromelalgia, and that significant clinical regression will be seen after stopping cabergoline treatment.